Galena enrolls first patient in phase II trial of GALE-301 cancer immunotherapy in ovarian cancer Jan. 9, 2014
FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC Jan. 7, 2014
RSS